Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline

Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 19, 2026

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201  -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2  data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight patients who completed dosing in Cohort 1 of the double-blinded, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiation of Cohort 2 at 12 mg/kg, a dose escalation from 6 mg/kg in Cohort 1.

GlobeNewsWire • Feb 17, 2026

Entrada Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m.

GlobeNewsWire • Feb 4, 2026

Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 – -- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and expects to nominate second clinical candidate in 2026 – -- Cash runway into Q3 2027 – -- Entrada to present at the 44 th  Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET) -- BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported progress across its robust development portfolio of RNA-based programs for the potential treatment of neuromuscular and ocular diseases.

GlobeNewsWire • Jan 8, 2026

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET).

GlobeNewsWire • Dec 17, 2025

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 40,650 restricted stock units (“RSUs”) and options to purchase 38,850 shares of the Company's common stock to five newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of December 1, 2025. The options have an exercise price of $9.91 per share, which is equal to the closing price of the Company's common stock on December 1, 2025.

GlobeNewsWire • Dec 4, 2025

Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts

Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration income. TRDA is heavily investing in its Duchenne muscular dystrophy pipeline, with multiple early-stage clinical programs converging on key data readouts in 2026. Despite widening losses, TRDA maintains a strong cash position of $326.8 million, sufficient to fund operations through 3Q27 and support ongoing R&D.

Seeking Alpha • Nov 17, 2025

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

-- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient cohort in mid-2026 -- -- Filed for regulatory authorization in U.K. to initiate ELEVATE-50-201, a global Phase 1/2 MAD clinical study of ENTR-601-50 -- -- Expected cash runway extended into Q3 2027 with  $327 million  in cash, cash equivalents and marketable securities as of September 30, 2025 -- BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the third quarter ended September 30, 2025, and highlighted recent business updates. “This year, we have strategically positioned Entrada to significantly advance what we believe to be best-in-class therapies for people living with Duchenne muscular dystrophy and their families.

GlobeNewsWire • Nov 6, 2025

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.35 per share a year ago.

Zacks Investment Research • Nov 6, 2025